News & Analysis as of

Pharmaceutical Industry Radiopharmaceuticals

McDermott Will & Emery

340B Covered Entities May See Access Changes to Contrast Media, Radiopharmaceuticals and Other Products

340B covered entities may experience expanded access to contrast media, radiopharmaceuticals and other products at 340B prices in the coming months. Buried in the over 1,600 pages of the Consolidated Appropriations Act, 2023...more

Smart & Biggar

Health Canada TPD, BRDD and NNHPD Annual Performance Reports released

Smart & Biggar on

The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission...more

Morgan Lewis - Up & Atom

NRC’s Report to Congress Identifies ‘Abnormal Occurrences’ at Licensed Medical Facilities

The US Nuclear Regulatory Commission (NRC) recently issued its Report to Congress on Abnormal Occurrences for fiscal year 2020. The report documents key aspects of those events that the NRC considers “Abnormal Occurrences”...more

Morgan Lewis

NRC’s Advisory Committee on the Medical Uses of Isotopes Discusses Radiopharmaceuticals, ‘Patient Intervention,’ and Medical...

Morgan Lewis on

The US Nuclear Regulatory Commission’s (NRC’s) Advisory Committee on the Medical Uses of Isotopes (ACMUI) held a meeting on March 30 to discuss a variety of topics of interest, including recent trends in radiopharmaceuticals,...more

Morgan Lewis

NRC Issues Guidance to Nuclear Materials Licensees in Response to Recent Medical Events

Morgan Lewis on

The NRC’s Office of Nuclear Reactor Regulation and Office of Nuclear Material Safety and Safety and Safeguards recently issued two Information Notices (INs) in response to medical events arising from the administration of...more

Manatt, Phelps & Phillips, LLP

Health Update - June 2015

Examining Fee Splitting Statutes in the Context of Value-Based Healthcare - Editor’s note: One of the goals of the Affordable Care Act (ACA) is to align incentives among provider communities and their patients and...more

Epstein Becker & Green

Federal Trade Commission Obtains a Near Record-Breaking Disgorgement in a Monopolization Case

Epstein Becker & Green on

On April 20, 2015, the Federal Trade Commission (“FTC”) announced that Cardinal Health, Inc. (“Cardinal”), agreed to pay $26.8 million to resolve allegations that it violated Section 2 of the Sherman Act by monopolizing the...more

Bracewell LLP

FTC Obtains $26.8 Million in Disgorgement to Settle Monopolization Claims

Bracewell LLP on

On April 17, 2015, the Federal Trade Commission (FTC) entered into a settlement with Cardinal Health, Inc. (Cardinal) to resolve allegations that Cardinal, the largest and in certain areas the sole operator of...more

8 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide